H.C. Wainwright lowered the firm’s price target on Viridian Therapeutics to $27 from $37 and keeps a Buy rating on the shares. The firm is taking a more conservative stance on thyroid eye disease market growth based on what it has seen from Tepezza of late.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRDN: